Biocon

Stocks to watch on January 16, 2026: Stocks like Infosys, ICICI Prudential AMC, Biocon, Angel One and HDB Financial Services will remain in focus today

Biotech firm Biocon on Thursday said it has raised Rs 4,150 crore through a Qualified Institutions Placement (QIP) process. The initiative saw issuance of 1,12,664,585 equity shares of face value Rs 5 each to eligible qualified institutional buyers at the issue price of Rs 368.35 per share, the Bengaluru-based firm said in a regulatory filing. The QIP, which opened on January 12 and closed on January 14, attracted strong investor interest from a broad mix of domestic and international participants, reflecting robust confidence in the company's growth prospects, it added. The proceeds from the QIP will be primarily utilised to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Ltd, including repayment of debt availed in this regard, Biocon said. The company recently announced its board has approved a strategic corporate action to acquire all remaining minority shareholdings, including Viatris' stake, thereby making Biocon

Stocks to watch on January 13, 2026: Stocks like TCS, HCL Technologies, Anand Rathi Wealth, Biocon and NBCC will remain in focus today

Biocon has opened a ₹4,500-crore QIP and fixed a floor price of ₹387.74 per share. The company said it may offer a discount of up to 5% and will finalise pricing with lead managers

Stocks to Watch today, January 7, 2026: Godrej Consumer, Titan, Jubilant FoodWorks, YES Bank are among key stocks that will be in focus today

Ajanta Pharma share price rose as it has entered into an in-licensing agreement with Biocon Limited for the right to market Semaglutide

Ajanta Pharma has signed an in-licensing pact with Biocon to market semaglutide across 26 countries in Africa, the Middle East and Central Asia, subject to approvals

Stocks to Watch today, December 16, 2025: HCLTech, MTNL, SBI, EIH and others will remain on investors' radar today

The Netherlands launch builds on Biocon's entry into the UK in February, where it received regulatory approval for liraglutide from the Medicines and Healthcare Products Regulatory Agency

Brokerages say Biocon's move to fully acquire Biocon Biologics simplifies structure and unlocks value, but near-term stock pressure likely due to dilution and fundraising

Stocks to Watch today, December 8, 2025: Bajaj Finserv, ONGC, AU Small Finance Bank, P N Gadgil Jewellers, Cochin Shipyard, Delhivery, and TVS Motor Company are among the top stock to remain in focus

'Can reinvest operating cash back into biz to scale up GLP-1s'

Proposed transaction will result in Biocon Biologics becoming a wholly-owned subsidiary of Biocon, simplifying the group structure, and strengthening the consolidated balance sheet

Biocon Biologics Chief Executive Shreehas Tambe will become CEO and managing director of the combined entity post-integration

Biocon's board will meet on December 6 to consider acquiring Biocon Biologics shares from minority investors through cash or a share swap, and to approve fundraising options such as QIP, rights issue

MOFSL and JM Financial retained their Buy ratings, while Nuvama upgraded Biocon to Buy from Hold after the company posted a net profit of ₹85 crore in Q2FY26

CEO Shreehas Tambe says debt reduction, US state tie-ups, and five fresh product launches will strengthen Biocon Biologics' global biosimilar play

The biosimilars segment, operated by Biocon Biologics, reported revenues of Rs 2,721 crore, reflecting strong 25 per cent year-on-year growth

Q2FY26 company results: Firms including Bajaj Holdings & Investment, Bharat Forge, Bosch, Cera Sanitaryware and Hindustan Copper are also to release their July-September earnings reports today

As regulators ease biosimilar trial norms, Syngene International is expanding into late-stage clinical supply production, betting on biologics and peptide manufacturing for growth